EMA to review Genmab, Pfizer’s MAA for tisotumab vedotin
Genmab and Pfizer’s marketing authorisation application (MAA) for Tisotumab vedotin, an antibody-drug conjugate (ADC) intended for the treatment…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Feb 24
Genmab and Pfizer’s marketing authorisation application (MAA) for Tisotumab vedotin, an antibody-drug conjugate (ADC) intended for the treatment…
05 Feb 24
The approval was based on the positive outcomes of the ReSTORE Phase 3 clinical trial in which rezafungin…
05 Feb 24
Inmagene has obtained an exclusive, worldwide and royalty-bearing license for the two drug candidates to further develop, manufacture…
02 Feb 24
Publicis Health has agreed to pay $350m to settle allegations made by all states and territories in the…
02 Feb 24
According to the long-term data, around 60% of people getting Vabysmo in BALATON and up to 48% of…
01 Feb 24
Rusfertide is an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin, which is currently in the…
31 Jan 24
In both randomised controlled trials for abdominoplasty and bunionectomy, treatment with VX-548 resulted in a statistically significant improvement…
31 Jan 24
Under the agreement, Regeneron will buy full development and commercialisation rights of 2seventy’s pipeline of investigational immune cell…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Jan 24
The funds will be used to advance the development of Cour’s Myasthenia Gravis and Type 1 Diabetes product…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
31 Jan 24
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced their enhanced QIAGEN CLC Genomics Workbench Premium…